thalidomide has been researched along with Cancer of Liver in 83 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC), and to date, no combination therapy has demonstrated superior survival compared with sorafenib alone." | 9.22 | Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. ( Althouse, SK; Chiorean, EG; Clark, RS; Loehrer, PJ; Shahda, S; Spittler, AJ, 2016) |
| "To correlate between signal parameters using dynamic contrast-enhanced magnetic resonance imaging (DCEMRI) and outcomes of hepatocellular carcinoma (HCC) receiving radiotherapy with or without concomitant thalidomide." | 9.20 | Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide. ( Ch'ang, HJ; Chen, LT; Hsu, C; Liang, PC; Liu, TW; Shih, TT, 2015) |
| "Thalidomide has been shown to have antitumor activity in some patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. ( Cheng, AL; Hsiao, CH; Hsu, C; Hsu, CH; Huang, CC; Lee, KD; Lin, ZZ; Lu, YS; Shao, YY; Shen, YC, 2012) |
| "Thalidomide has been demonstrated to possess antitumor activity in patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. ( Ch'ang, HJ; Chang, JS; Chang, YH; Chen, CH; Chen, LT; Hsu, C, 2012) |
| "4 years; range, 20-81 years) with advanced hepatocellular carcinoma received three-dimensional conformal radiotherapy and thalidomide." | 9.12 | Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. ( Chan, SC; Chao, CJ; Chung, NN; Hsu, WC; Lin, GD; Shin, JS; Ting, LL; Wang, PM; Ying, KS, 2006) |
| "To evaluate the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics of thalidomide in patients with advanced hepatocellular carcinoma (HCC)." | 9.12 | Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. ( Chang, JY; Chao, Y; Chen, LT; Chen, PJ; Chin, YH; Chuang, TR; Huang, JD; Liu, TW; Shiah, HS; Whang-Peng, J; Yao, TJ, 2006) |
| "Thalidomide, an anti-angiogenic agent, does not have a good therapeutic effect for advanced hepatocellular carcinoma when used alone." | 9.11 | Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study. ( Bendini, C; Bernardi, M; Cantarini, MC; Cappa, FM; Magini, G; Santi, V; Trevisani, F; Zambruni, A, 2005) |
| "From March 2000 to July 2002, patients who had advanced hepatocellular carcinoma and failed to or were unsuited for aggressive treatment, were enrolled and took thalidomide 150 to 300 mg/d." | 9.11 | Salvage therapy for hepatocellular carcinoma with thalidomide. ( Chang, WH; Chu, CH; Hsieh, RK; Kao, CR; Lin, J; Lin, SC; Wang, TE, 2004) |
| "Transcatheter arterial chemoembolization (TACE) and thalidomide have been used for treating primary hepatocellular carcinoma(HCC)." | 8.95 | Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis. ( Cao, DD; Gao, SF; Ge, W; Liu, L; Xu, HL; Xu, XM; Zheng, YF, 2017) |
| "The immune modulatory drug lenalidomide has shown promising anti-tumor activity in a clinical trial of patients with advanced hepatocellular carcinoma (HCC)." | 7.80 | Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. ( Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL, 2014) |
| "Thalidomide has shown modest activity in advanced hepatocellular carcinomas (HCCs)." | 7.78 | Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. ( Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC, 2012) |
| "We reported two cases of hepatocellular carcinoma (HCC) with lung metastases who were treated with a combination of thalidomide and cyproheptadine." | 7.78 | Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study. ( Chen, SC; Feng, CW; Feng, YM; Hsu, CD, 2012) |
| "To evaluate the efficacy of thalidomide in combination with other therapies to treat patients with advanced hepatocellular carcinoma (HCC)." | 7.78 | Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis. ( Chen, YY; Chou, KC; Wu, SS; Yen, HH, 2012) |
| "The present study developed a validate and precise reversed-phase high performance liquid chromatography (HPLC) method for the determination of thalidomide (T) in plasma, to quantify T in patients affected by hepatocellular carcinoma." | 7.74 | High performance liquid chromatographic determination of thalidomide in patients affected by hepatocellular carcinoma. ( Giorgi, M; Jemos, C; Macchia, M; Manera, C; Placanica, G; Saccomanni, G; Salè, EO; Turini, V, 2008) |
| "Thalidomide and its analogs have been extensively studied in patients with multiple myeloma." | 7.73 | Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005) |
| "alpha-fetoprotein response can more accurately reflect the biological response of advanced hepatocellular carcinoma to thalidomide therapy than radiographic response." | 7.73 | alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. ( Chang, JY; Chao, Y; Chen, LT; Chen, SC; Chin, YH; Chuang, TR; Juang, SH; Liu, TW; Shiah, HS; Whang-Peng, J, 2005) |
| "Higher vascularity index may be associated with a better chance of response to thalidomide in patients with advanced hepatocellular carcinoma." | 7.73 | Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. ( Chen, CN; Chen, LT; Cheng, AL; Hsieh, FJ; Hsu, C; Wu, CY, 2005) |
| "To evaluate which patients with hepatocellular carcinoma (HCC) are most likely to respond to thalidomide treatment." | 7.73 | Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. ( Chiou, HE; Liu, HW; Wang, TE; Wang, YY, 2006) |
| "Thalidomide can significantly inhibit angiogenesis and metastasis of hepatocellular carcinoma." | 7.73 | Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. ( Liu, ZS; Sun, Q; Zhang, ZL, 2005) |
| "Thalidomide has been reported to have antitumor activity for treating metastatic hepatocellular carcinoma (HCC)." | 7.73 | Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study. ( Bang, SM; Cho, EK; Han, SH; Kim, JH; Kim, KK; Kim, SS; Kwon, OS; Kwon, SY; Lee, JH; Lee, JJ; Lee, JN; Nam, E; Park, SH; Park, YH; Shin, DB, 2006) |
| "We sought to investigate whether thalidomide is able to produce tumor vascular changes in patients with untreatable hepatocellular carcinoma (HCC) that can be detected using microbubble contrast agents." | 7.73 | Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results. ( Bertolotto, M; Cova, MA; Crocè, LS; Gasparini, C; Nascimben, F; Pozzato, G; Tiribelli, C, 2006) |
| "To evaluate thalidomide in advanced hepatocellular carcinoma (HCC) and to evaluate combined thalidomide and low-dose interferon-alpha2a (IFN-alpha2a) after tumor progression on thalidomide." | 7.73 | Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. ( Goldenberg, A; Lehrer, D; Liebes, L; Mandeli, J; Schwartz, JD; Schwartz, M; Sung, M; Volm, M, 2005) |
| "To analyze the efficacy of oral thalidomide in the treatment of advanced hepatocellular carcinoma (HCC)." | 7.72 | Low-dose thalidomide treatment for advanced hepatocellular carcinoma. ( Chen, CN; Chen, LT; Cheng, AL; Hsu, C; Lai, MY; Lee, PH; Wu, CY; Yang, PM, 2003) |
| "advanced hepatocellular carcinoma (HCC) AIM: To explore potential biomarkers of lenalidomide efficacy as second-line therapy for HCC." | 6.84 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ, 2017) |
| "Thalidomide and TACE were commonly associated with nonhematologic side effects, with fatigue and constipation being prominent." | 6.79 | Chronic thalidomide and chemoembolization for hepatocellular carcinoma. ( Christos, PJ; Goldenberg, AS; Hochster, HS; Muggia, FM; Ng, J; Sparano, J; Sung, MW; Wu, J, 2014) |
| " The initial thalidomide dosage of 100 mg/day was escalated in 100 mg steps weekly up to 300 mg/day based on tolerability." | 6.73 | Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. ( Müller, C; Peck-Radosavljevic, M; Pinter, M; Plank, C; Schmid, K; Wichlas, M; Wrba, F, 2008) |
| "Thalidomide is an antiangiogenic agent with activity in refractory multiple myeloma." | 6.73 | Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. ( Boyer, M; Chuah, B; Clarke, S; Goh, BC; Kong, HL; Lim, R; Millward, M; Ong, AB; Wong, SW, 2007) |
| "The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents." | 6.71 | Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. ( Abbruzzese, JL; Brown, TD; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Zeldis, JB, 2005) |
| "The hypervascular nature of hepatocellular carcinoma (HCC) is well characterized." | 6.71 | Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. ( Biggs, C; Brophy, N; Fisher, GA; Levitt, L; Lin, AY; So, S; Yock, TI, 2005) |
| "(TACE) for treating liver cancer." | 6.58 | Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach ( Chen, Y; Hong, Q; Huang, L; Kang, D; Wang, D; Wen, S; Yang, W, 2018) |
| "In patients with advanced hepatocellular carcinoma (HCC), inferior vena cava/intra-right atrial (IVC/RA) tumor thrombi are not uncommon findings and are usually associated with extremely poor outcome." | 6.42 | Hepatocellular carcinoma with intra-atrial tumor thrombi. A report of three cases responsive to thalidomide treatment and literature review. ( Chang, JY; Chao, TY; Chen, LT; Chuang, TR; Ka, WS; Liu, TW, 2004) |
| "Advanced stage liver cancer is predominantly treated with the multi-kinase inhibitor sorafenib; however, this therapeutic agent lacks selectivity in its cytotoxic actions and is associated with poor survival outcomes." | 5.62 | In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties. ( Andrewartha, N; Buyan, A; Corry, B; Nutt, MJ; Stewart, SG; Yee, YS; Yeoh, GCT, 2021) |
| "Lenalidomide is a novel analogue of thalidomide and has anti‑inflammatory, immunomodulatory and anti‑angiogenic effects." | 5.43 | Lenalidomide induces apoptosis and inhibits angiogenesis via caspase‑3 and VEGF in hepatocellular carcinoma cells. ( Ding, Y; Jiang, C; Qu, Z; Wu, J, 2016) |
| "Curative treatment of aggressive Kaposi sarcoma (KS) with conventional chemotherapy in human immunodeficiency virus (HIV)-infected patients remains difficult." | 5.39 | Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma. ( Burg, S; Crickx, B; Di Lucca, J; Feldman, J; Joly, V; Lariven, S; Marinho, E; Maubec, E; Peytavin, G; Raymond, E; Sarda-Mantel, L; Steff, M, 2013) |
| "The systemic treatment of advanced hepatocellular carcinoma (HCC) has produced disappointing results thus far." | 5.34 | Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. ( Chan, P; Cheung, TT; Chok, SH; Epstein, RJ; Fan, ST; Lam, V; Ng, KK; Poon, RT; Wong, H; Yau, T, 2007) |
| "Thalidomide was administered daily at doses ranging from 50 to 300 mg/kg by intraperitoneal injection." | 5.33 | Effect of thalidomide on colorectal cancer liver metastases in CBA mice. ( Christophi, C; Daruwalla, J; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2005) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC), and to date, no combination therapy has demonstrated superior survival compared with sorafenib alone." | 5.22 | Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. ( Althouse, SK; Chiorean, EG; Clark, RS; Loehrer, PJ; Shahda, S; Spittler, AJ, 2016) |
| "To correlate between signal parameters using dynamic contrast-enhanced magnetic resonance imaging (DCEMRI) and outcomes of hepatocellular carcinoma (HCC) receiving radiotherapy with or without concomitant thalidomide." | 5.20 | Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide. ( Ch'ang, HJ; Chen, LT; Hsu, C; Liang, PC; Liu, TW; Shih, TT, 2015) |
| "Thalidomide has been shown to have antitumor activity in some patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. ( Cheng, AL; Hsiao, CH; Hsu, C; Hsu, CH; Huang, CC; Lee, KD; Lin, ZZ; Lu, YS; Shao, YY; Shen, YC, 2012) |
| "Thalidomide has been demonstrated to possess antitumor activity in patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. ( Ch'ang, HJ; Chang, JS; Chang, YH; Chen, CH; Chen, LT; Hsu, C, 2012) |
| "To evaluate the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics of thalidomide in patients with advanced hepatocellular carcinoma (HCC)." | 5.12 | Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. ( Chang, JY; Chao, Y; Chen, LT; Chen, PJ; Chin, YH; Chuang, TR; Huang, JD; Liu, TW; Shiah, HS; Whang-Peng, J; Yao, TJ, 2006) |
| "4 years; range, 20-81 years) with advanced hepatocellular carcinoma received three-dimensional conformal radiotherapy and thalidomide." | 5.12 | Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. ( Chan, SC; Chao, CJ; Chung, NN; Hsu, WC; Lin, GD; Shin, JS; Ting, LL; Wang, PM; Ying, KS, 2006) |
| "Thalidomide, an anti-angiogenic agent, does not have a good therapeutic effect for advanced hepatocellular carcinoma when used alone." | 5.11 | Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study. ( Bendini, C; Bernardi, M; Cantarini, MC; Cappa, FM; Magini, G; Santi, V; Trevisani, F; Zambruni, A, 2005) |
| "From March 2000 to July 2002, patients who had advanced hepatocellular carcinoma and failed to or were unsuited for aggressive treatment, were enrolled and took thalidomide 150 to 300 mg/d." | 5.11 | Salvage therapy for hepatocellular carcinoma with thalidomide. ( Chang, WH; Chu, CH; Hsieh, RK; Kao, CR; Lin, J; Lin, SC; Wang, TE, 2004) |
| "Transcatheter arterial chemoembolization (TACE) and thalidomide have been used for treating primary hepatocellular carcinoma(HCC)." | 4.95 | Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis. ( Cao, DD; Gao, SF; Ge, W; Liu, L; Xu, HL; Xu, XM; Zheng, YF, 2017) |
| "The immune modulatory drug lenalidomide has shown promising anti-tumor activity in a clinical trial of patients with advanced hepatocellular carcinoma (HCC)." | 3.80 | Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. ( Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL, 2014) |
| " In a heavily pretreated patient with advanced colorectal cancer carrying mutations in APC and KRAS genes, we show an early metabolic response and enhanced NK cell activity to monotherapy with lenalidomide." | 3.80 | Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. ( Amann, A; Auer, T; Gamerith, G; Hilbe, W; Kircher, B; Loeffler-Ragg, J; Putzer, D; Schenk, B; Zwierzina, H, 2014) |
| "We reported two cases of hepatocellular carcinoma (HCC) with lung metastases who were treated with a combination of thalidomide and cyproheptadine." | 3.78 | Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study. ( Chen, SC; Feng, CW; Feng, YM; Hsu, CD, 2012) |
| "To evaluate the efficacy of thalidomide in combination with other therapies to treat patients with advanced hepatocellular carcinoma (HCC)." | 3.78 | Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis. ( Chen, YY; Chou, KC; Wu, SS; Yen, HH, 2012) |
| "Thalidomide has shown modest activity in advanced hepatocellular carcinomas (HCCs)." | 3.78 | Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. ( Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC, 2012) |
| "The aim of this study was to investigate the effect of thalidomide on the growth of human hepatoma cell line SMMC-7721 cells in vitro, and to explore the curative possibility of hepatocellular carcinoma with thalidomide." | 3.75 | [Inhibitory effect of thalidomide on growth of human hepatoma cell line SMMC-7721 cells]. ( Dong, LL; Sun, DJ; Sun, P; Zhang, LM, 2009) |
| "The present study developed a validate and precise reversed-phase high performance liquid chromatography (HPLC) method for the determination of thalidomide (T) in plasma, to quantify T in patients affected by hepatocellular carcinoma." | 3.74 | High performance liquid chromatographic determination of thalidomide in patients affected by hepatocellular carcinoma. ( Giorgi, M; Jemos, C; Macchia, M; Manera, C; Placanica, G; Saccomanni, G; Salè, EO; Turini, V, 2008) |
| "Thalidomide can significantly inhibit angiogenesis and metastasis of hepatocellular carcinoma." | 3.73 | Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. ( Liu, ZS; Sun, Q; Zhang, ZL, 2005) |
| " Although treatment was initiated with thalidomide, the patient developed multiple organ dysfunction syndrome (MODS) and succumbed to his disease." | 3.73 | Multifocal epithelioid hemangioendothelioma: case report of a clinical chamaeleon. ( Bölke, E; Budach, W; Gripp, S; Orth, K; Peiper, M; Reinecke, P; Schwarz, A; van de Nes, JA, 2006) |
| "Thalidomide and its analogs have been extensively studied in patients with multiple myeloma." | 3.73 | Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005) |
| "To evaluate which patients with hepatocellular carcinoma (HCC) are most likely to respond to thalidomide treatment." | 3.73 | Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. ( Chiou, HE; Liu, HW; Wang, TE; Wang, YY, 2006) |
| "Higher vascularity index may be associated with a better chance of response to thalidomide in patients with advanced hepatocellular carcinoma." | 3.73 | Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. ( Chen, CN; Chen, LT; Cheng, AL; Hsieh, FJ; Hsu, C; Wu, CY, 2005) |
| "alpha-fetoprotein response can more accurately reflect the biological response of advanced hepatocellular carcinoma to thalidomide therapy than radiographic response." | 3.73 | alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. ( Chang, JY; Chao, Y; Chen, LT; Chen, SC; Chin, YH; Chuang, TR; Juang, SH; Liu, TW; Shiah, HS; Whang-Peng, J, 2005) |
| "To evaluate thalidomide in advanced hepatocellular carcinoma (HCC) and to evaluate combined thalidomide and low-dose interferon-alpha2a (IFN-alpha2a) after tumor progression on thalidomide." | 3.73 | Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. ( Goldenberg, A; Lehrer, D; Liebes, L; Mandeli, J; Schwartz, JD; Schwartz, M; Sung, M; Volm, M, 2005) |
| "We sought to investigate whether thalidomide is able to produce tumor vascular changes in patients with untreatable hepatocellular carcinoma (HCC) that can be detected using microbubble contrast agents." | 3.73 | Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results. ( Bertolotto, M; Cova, MA; Crocè, LS; Gasparini, C; Nascimben, F; Pozzato, G; Tiribelli, C, 2006) |
| "Thalidomide has been reported to have antitumor activity for treating metastatic hepatocellular carcinoma (HCC)." | 3.73 | Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study. ( Bang, SM; Cho, EK; Han, SH; Kim, JH; Kim, KK; Kim, SS; Kwon, OS; Kwon, SY; Lee, JH; Lee, JJ; Lee, JN; Nam, E; Park, SH; Park, YH; Shin, DB, 2006) |
| "To analyze the efficacy of oral thalidomide in the treatment of advanced hepatocellular carcinoma (HCC)." | 3.72 | Low-dose thalidomide treatment for advanced hepatocellular carcinoma. ( Chen, CN; Chen, LT; Cheng, AL; Hsu, C; Lai, MY; Lee, PH; Wu, CY; Yang, PM, 2003) |
| "To evaluate the perfusion changes in advanced hepatocellular carcinoma (HCC) treated with the antiangiogenic agent thalidomide, we used dynamic contrast-enhanced MRI." | 3.72 | Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. ( Chen, LT; Liu, TW; Shih, TT; Tsang, YM; Wang, J, 2004) |
| "advanced hepatocellular carcinoma (HCC) AIM: To explore potential biomarkers of lenalidomide efficacy as second-line therapy for HCC." | 2.84 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ, 2017) |
| "Thalidomide and TACE were commonly associated with nonhematologic side effects, with fatigue and constipation being prominent." | 2.79 | Chronic thalidomide and chemoembolization for hepatocellular carcinoma. ( Christos, PJ; Goldenberg, AS; Hochster, HS; Muggia, FM; Ng, J; Sparano, J; Sung, MW; Wu, J, 2014) |
| " The initial thalidomide dosage of 100 mg/day was escalated in 100 mg steps weekly up to 300 mg/day based on tolerability." | 2.73 | Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. ( Müller, C; Peck-Radosavljevic, M; Pinter, M; Plank, C; Schmid, K; Wichlas, M; Wrba, F, 2008) |
| "Thalidomide is an antiangiogenic agent with activity in refractory multiple myeloma." | 2.73 | Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. ( Boyer, M; Chuah, B; Clarke, S; Goh, BC; Kong, HL; Lim, R; Millward, M; Ong, AB; Wong, SW, 2007) |
| "The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents." | 2.71 | Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. ( Abbruzzese, JL; Brown, TD; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Zeldis, JB, 2005) |
| "The hypervascular nature of hepatocellular carcinoma (HCC) is well characterized." | 2.71 | Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. ( Biggs, C; Brophy, N; Fisher, GA; Levitt, L; Lin, AY; So, S; Yock, TI, 2005) |
| "(TACE) for treating liver cancer." | 2.58 | Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach ( Chen, Y; Hong, Q; Huang, L; Kang, D; Wang, D; Wen, S; Yang, W, 2018) |
| "In patients with advanced hepatocellular carcinoma (HCC), inferior vena cava/intra-right atrial (IVC/RA) tumor thrombi are not uncommon findings and are usually associated with extremely poor outcome." | 2.42 | Hepatocellular carcinoma with intra-atrial tumor thrombi. A report of three cases responsive to thalidomide treatment and literature review. ( Chang, JY; Chao, TY; Chen, LT; Chuang, TR; Ka, WS; Liu, TW, 2004) |
| "Thalidomide has been shown to block the activity of angiogenic substances like bFGF, VEGF and interleukin 6." | 2.41 | [Thalidomide. Clinical trials in cancer]. ( Politi, PM, 2000) |
| " In addition, antiangiogenic agents may be valuable for long-term administration to maintain tumor dormancy, because drug resistance does not develop and these agents have a sustained effect." | 2.40 | Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies. ( Baba, M; Kanai, T; Konno, H; Nakamura, S; Tanaka, T, 1999) |
| "Advanced stage liver cancer is predominantly treated with the multi-kinase inhibitor sorafenib; however, this therapeutic agent lacks selectivity in its cytotoxic actions and is associated with poor survival outcomes." | 1.62 | In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties. ( Andrewartha, N; Buyan, A; Corry, B; Nutt, MJ; Stewart, SG; Yee, YS; Yeoh, GCT, 2021) |
| "Lenalidomide is a novel analogue of thalidomide and has anti‑inflammatory, immunomodulatory and anti‑angiogenic effects." | 1.43 | Lenalidomide induces apoptosis and inhibits angiogenesis via caspase‑3 and VEGF in hepatocellular carcinoma cells. ( Ding, Y; Jiang, C; Qu, Z; Wu, J, 2016) |
| "Fibrolamellar variant of hepatocellular carcinoma (FLHCC) does not have a favorable prognosis than conventional HCC, and there is no difference regarding the response to chemotherapy and the degree of surgical resectability." | 1.40 | Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child. ( Akdemir, ÜÖ; Akyol, G; Boyunağa, Ö; Dalgiç, A; Demiroğullari, B; Eser, EP; Karadeniz, C; Oğuz, A; Okur, A; Pinarli, FG; Yilmaz, G, 2014) |
| "Curative treatment of aggressive Kaposi sarcoma (KS) with conventional chemotherapy in human immunodeficiency virus (HIV)-infected patients remains difficult." | 1.39 | Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma. ( Burg, S; Crickx, B; Di Lucca, J; Feldman, J; Joly, V; Lariven, S; Marinho, E; Maubec, E; Peytavin, G; Raymond, E; Sarda-Mantel, L; Steff, M, 2013) |
| "Treatment with thalidomide resulted in a significant decrease in perfusion scores assigned to AUC, IMAX and PI parametric images as compared with control tumors (P < 0." | 1.38 | Contrast-enhanced ultrasonic parametric perfusion imaging in the evaluation of antiangiogenic tumor treatment. ( Cao, LH; Han, F; Li, AH; Liu, M; Luo, RZ; Wu, PH; Zheng, W; Zhou, JH, 2012) |
| " Rats with implanted liver tumors were randomized into four treatment groups: 1) Zd6126 (Zd); 2) Thalidomide (Tha); 3) Zd in combination with Tha (ZdTha); and 4) controls." | 1.38 | Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI. ( Chen, F; Cona, MM; De Geest, B; De Keyzer, F; Feng, Y; Jiang, Y; Li, J; Marchal, G; Ni, Y; Oyen, R; Verfaillie, C; Wang, H; Yu, J; Zheng, K, 2012) |
| "Hepatic metastasis from colorectal cancer (mCRC) is best treated with a multidisciplinary approach." | 1.35 | Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. ( Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE, 2009) |
| "The systemic treatment of advanced hepatocellular carcinoma (HCC) has produced disappointing results thus far." | 1.34 | Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. ( Chan, P; Cheung, TT; Chok, SH; Epstein, RJ; Fan, ST; Lam, V; Ng, KK; Poon, RT; Wong, H; Yau, T, 2007) |
| "Celecoxib is a potent selective COX-2 inhibitor." | 1.33 | [A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine]. ( Hada, M; Horiuchi, T; Shinji, H, 2006) |
| "Thalidomide was administered daily at doses ranging from 50 to 300 mg/kg by intraperitoneal injection." | 1.33 | Effect of thalidomide on colorectal cancer liver metastases in CBA mice. ( Christophi, C; Daruwalla, J; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2005) |
| "Thalidomide cannot inhibit VEGF mRNA expression of grafted H22 tumor in mouse." | 1.32 | [Effect of thalidomide on tumor growth in mouse hepatoma H22 model]. ( Lu, ZJ; Zhai, Y, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (6.02) | 18.7374 |
| 1990's | 2 (2.41) | 18.2507 |
| 2000's | 45 (54.22) | 29.6817 |
| 2010's | 29 (34.94) | 24.3611 |
| 2020's | 2 (2.41) | 2.80 |
| Authors | Studies |
|---|---|
| Woo, K | 1 |
| Stewart, SG | 2 |
| Kong, GS | 1 |
| Finch-Edmondson, ML | 1 |
| Dwyer, BJ | 1 |
| Yeung, SY | 1 |
| Abraham, LJ | 1 |
| Kampmann, SS | 1 |
| Diepeveen, LA | 1 |
| Passman, AM | 1 |
| Elsegood, CL | 1 |
| Tirnitz-Parker, JE | 1 |
| Callus, BA | 1 |
| Olynyk, JK | 1 |
| Yeoh, GC | 1 |
| Nutt, MJ | 1 |
| Yee, YS | 1 |
| Buyan, A | 1 |
| Andrewartha, N | 1 |
| Corry, B | 1 |
| Yeoh, GCT | 1 |
| Ramírez-Flores, PN | 1 |
| Barraza-Reyna, PJ | 1 |
| Aguirre-Vázquez, A | 1 |
| Camacho-Moll, ME | 1 |
| Guerrero-Beltrán, CE | 1 |
| Resendez-Pérez, D | 1 |
| González-Villasana, V | 1 |
| Garza-González, JN | 1 |
| Silva-Ramírez, B | 1 |
| Castorena-Torres, F | 1 |
| Bermúdez de León, M | 1 |
| Cao, DD | 1 |
| Xu, HL | 1 |
| Liu, L | 1 |
| Zheng, YF | 1 |
| Gao, SF | 1 |
| Xu, XM | 1 |
| Ge, W | 1 |
| Shao, YY | 2 |
| Chen, BB | 1 |
| Ou, DL | 2 |
| Lin, ZZ | 3 |
| Hsu, CH | 2 |
| Wang, MJ | 1 |
| Cheng, AL | 5 |
| Hsu, C | 7 |
| Yang, W | 1 |
| Wang, D | 1 |
| Huang, L | 1 |
| Chen, Y | 2 |
| Wen, S | 1 |
| Hong, Q | 1 |
| Kang, D | 1 |
| Safran, H | 1 |
| Charpentier, KP | 1 |
| Kaubisch, A | 1 |
| Mantripragada, K | 1 |
| Dubel, G | 1 |
| Perez, K | 1 |
| Faricy-Anderson, K | 1 |
| Miner, T | 1 |
| Eng, Y | 1 |
| Victor, J | 1 |
| Plette, A | 1 |
| Espat, J | 1 |
| Bakalarski, P | 1 |
| Wingate, P | 1 |
| Berz, D | 1 |
| Luppe, D | 1 |
| Martel, D | 1 |
| Rosati, K | 1 |
| Aparo, S | 1 |
| Steff, M | 1 |
| Joly, V | 1 |
| Di Lucca, J | 1 |
| Feldman, J | 1 |
| Burg, S | 1 |
| Sarda-Mantel, L | 1 |
| Peytavin, G | 1 |
| Marinho, E | 1 |
| Crickx, B | 1 |
| Raymond, E | 1 |
| Lariven, S | 1 |
| Maubec, E | 1 |
| Nagy, LI | 1 |
| Molnár, E | 1 |
| Kanizsai, I | 1 |
| Madácsi, R | 1 |
| Ózsvári, B | 1 |
| Fehér, LZ | 1 |
| Fábián, G | 1 |
| Marton, A | 1 |
| Vizler, C | 1 |
| Ayaydin, F | 1 |
| Kitajka, K | 1 |
| Hackler, L | 1 |
| Mátés, L | 1 |
| Deák, F | 1 |
| Kiss, I | 1 |
| Puskás, LG | 1 |
| Gamerith, G | 1 |
| Auer, T | 1 |
| Amann, A | 1 |
| Putzer, D | 1 |
| Schenk, B | 1 |
| Kircher, B | 1 |
| Hilbe, W | 1 |
| Zwierzina, H | 1 |
| Loeffler-Ragg, J | 1 |
| Okur, A | 1 |
| Eser, EP | 1 |
| Yilmaz, G | 1 |
| Dalgiç, A | 1 |
| Akdemir, ÜÖ | 1 |
| Oğuz, A | 1 |
| Karadeniz, C | 1 |
| Akyol, G | 1 |
| Demiroğullari, B | 1 |
| Boyunağa, Ö | 1 |
| Pinarli, FG | 1 |
| Pallotti, MC | 1 |
| Nannini, M | 1 |
| Agostinelli, C | 1 |
| Leoni, S | 1 |
| Scioscio, VD | 1 |
| Mandrioli, A | 1 |
| Lolli, C | 1 |
| Saponara, M | 1 |
| Pileri, S | 1 |
| Bolondi, L | 1 |
| Biasco, G | 1 |
| Pantaleo, MA | 1 |
| Chang, CJ | 1 |
| Jeng, YM | 1 |
| Lin, YJ | 1 |
| Gandhi, AK | 1 |
| Liao, SC | 1 |
| Huang, ZM | 1 |
| Wu, J | 2 |
| Ng, J | 1 |
| Christos, PJ | 1 |
| Goldenberg, AS | 1 |
| Sparano, J | 1 |
| Sung, MW | 1 |
| Hochster, HS | 1 |
| Muggia, FM | 1 |
| Liang, PC | 1 |
| Ch'ang, HJ | 2 |
| Chen, LT | 9 |
| Shih, TT | 2 |
| Liu, TW | 5 |
| Kudo, M | 1 |
| Gurung, S | 1 |
| Fu, H | 1 |
| Zhang, WW | 1 |
| Gu, YH | 1 |
| Wang-Yuan, Z | 1 |
| Jiang-Zheng, Z | 1 |
| Lu, YD | 1 |
| Hao, XB | 1 |
| Hong, T | 1 |
| Huang, F | 1 |
| Lei, JH | 1 |
| He, ZH | 1 |
| Huang, MZ | 1 |
| Shahda, S | 1 |
| Loehrer, PJ | 1 |
| Clark, RS | 1 |
| Spittler, AJ | 1 |
| Althouse, SK | 1 |
| Chiorean, EG | 1 |
| Qu, Z | 1 |
| Jiang, C | 1 |
| Ding, Y | 1 |
| Pinter, M | 1 |
| Wichlas, M | 1 |
| Schmid, K | 1 |
| Plank, C | 1 |
| Müller, C | 1 |
| Wrba, F | 1 |
| Peck-Radosavljevic, M | 1 |
| Kassam, A | 1 |
| Mandel, K | 1 |
| Harshman, LC | 1 |
| Li, M | 1 |
| Srinivas, S | 2 |
| Scoggins, CR | 1 |
| Campbell, ML | 1 |
| Landry, CS | 1 |
| Slomiany, BA | 1 |
| Woodall, CE | 1 |
| McMasters, KM | 1 |
| Martin, RC | 1 |
| Yau, T | 2 |
| Chan, P | 2 |
| Epstein, R | 1 |
| Poon, RT | 2 |
| Liu, Y | 1 |
| Li, H | 1 |
| Matsui, O | 1 |
| Sun, P | 1 |
| Zhang, LM | 1 |
| Sun, DJ | 1 |
| Dong, LL | 1 |
| Wang, Z | 1 |
| Li, Z | 1 |
| Chen, CH | 1 |
| Chang, YH | 1 |
| Chang, JS | 1 |
| Zhou, JH | 1 |
| Zheng, W | 1 |
| Cao, LH | 1 |
| Liu, M | 1 |
| Luo, RZ | 1 |
| Han, F | 1 |
| Wu, PH | 1 |
| Li, AH | 1 |
| Ang, SF | 1 |
| Tan, SH | 1 |
| Toh, HC | 1 |
| Poon, DY | 1 |
| Ong, SY | 1 |
| Foo, KF | 1 |
| Choo, SP | 1 |
| Kayaci, S | 1 |
| Yildiz, O | 1 |
| Gucer, H | 1 |
| Mandel, NM | 1 |
| Lee, KD | 1 |
| Hsiao, CH | 1 |
| Lu, YS | 1 |
| Huang, CC | 1 |
| Shen, YC | 1 |
| Chen, YY | 1 |
| Yen, HH | 1 |
| Chou, KC | 1 |
| Wu, SS | 1 |
| Stewart, EE | 1 |
| Sun, H | 1 |
| Chen, X | 1 |
| Schafer, PH | 1 |
| Garcia, BM | 1 |
| Lee, TY | 1 |
| Saboo, SS | 1 |
| Fennessy, F | 1 |
| Benajiba, L | 1 |
| Laubach, J | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Chen, F | 1 |
| Feng, Y | 2 |
| Zheng, K | 1 |
| De Keyzer, F | 1 |
| Li, J | 1 |
| Cona, MM | 1 |
| Wang, H | 1 |
| Jiang, Y | 1 |
| Yu, J | 1 |
| Marchal, G | 1 |
| Verfaillie, C | 1 |
| De Geest, B | 1 |
| Oyen, R | 1 |
| Ni, Y | 1 |
| Feng, YM | 1 |
| Feng, CW | 1 |
| Chen, SC | 3 |
| Hsu, CD | 1 |
| Haidar, JH | 1 |
| Bazarbachi, A | 1 |
| Nasr, MR | 1 |
| El-Sabban, ME | 1 |
| Daher, R | 1 |
| ROE, FJ | 3 |
| MITCHLEY, BC | 2 |
| Chen, CN | 2 |
| Wu, CY | 2 |
| Yang, PM | 1 |
| Lai, MY | 1 |
| Lee, PH | 1 |
| Zhai, Y | 1 |
| Lu, ZJ | 1 |
| Fraiman, G | 1 |
| Ganti, AK | 1 |
| Potti, A | 1 |
| Mehdi, S | 1 |
| Wang, TE | 2 |
| Kao, CR | 1 |
| Lin, SC | 1 |
| Chang, WH | 1 |
| Chu, CH | 1 |
| Lin, J | 1 |
| Hsieh, RK | 1 |
| Wang, J | 1 |
| Tsang, YM | 1 |
| Chang, JY | 3 |
| Ka, WS | 1 |
| Chao, TY | 1 |
| Chuang, TR | 3 |
| Lin, AY | 1 |
| Brophy, N | 1 |
| Fisher, GA | 1 |
| So, S | 1 |
| Biggs, C | 1 |
| Yock, TI | 1 |
| Levitt, L | 1 |
| Wadler, S | 1 |
| Zhang, ZL | 1 |
| Liu, ZS | 1 |
| Sun, Q | 1 |
| Patt, YZ | 2 |
| Hassan, MM | 2 |
| Lozano, RD | 2 |
| Nooka, AK | 1 |
| Schnirer, II | 1 |
| Zeldis, JB | 1 |
| Abbruzzese, JL | 1 |
| Brown, TD | 1 |
| Mascarenhas, RC | 1 |
| Sanghvi, AN | 1 |
| Friedlander, L | 1 |
| Geyer, SJ | 1 |
| Beasley, HS | 1 |
| Van Thiel, DH | 1 |
| del Giglio, A | 1 |
| Weinschenker, P | 1 |
| Manhani, AR | 1 |
| Carbonell, AL | 1 |
| Mitteldorf, CA | 1 |
| Cipriani, G | 1 |
| Mazzanti, R | 1 |
| Cappa, FM | 1 |
| Cantarini, MC | 1 |
| Magini, G | 1 |
| Zambruni, A | 1 |
| Bendini, C | 1 |
| Santi, V | 1 |
| Bernardi, M | 1 |
| Trevisani, F | 1 |
| Hsieh, FJ | 1 |
| Daruwalla, J | 1 |
| Nikfarjam, M | 1 |
| Malcontenti-Wilson, C | 1 |
| Muralidharan, V | 1 |
| Christophi, C | 1 |
| Chao, Y | 2 |
| Shiah, HS | 2 |
| Juang, SH | 1 |
| Chin, YH | 2 |
| Whang-Peng, J | 2 |
| Guardino, AE | 1 |
| Schwartz, JD | 1 |
| Sung, M | 1 |
| Schwartz, M | 1 |
| Lehrer, D | 1 |
| Mandeli, J | 1 |
| Liebes, L | 1 |
| Goldenberg, A | 1 |
| Volm, M | 1 |
| Bertolotto, M | 1 |
| Pozzato, G | 1 |
| Crocè, LS | 1 |
| Nascimben, F | 1 |
| Gasparini, C | 1 |
| Cova, MA | 1 |
| Tiribelli, C | 1 |
| Lee, CC | 1 |
| Wu, YH | 1 |
| Chung, SH | 1 |
| Chen, WJ | 1 |
| Hada, M | 1 |
| Horiuchi, T | 1 |
| Shinji, H | 1 |
| Hsu, WC | 1 |
| Chan, SC | 1 |
| Ting, LL | 1 |
| Chung, NN | 1 |
| Wang, PM | 1 |
| Ying, KS | 1 |
| Shin, JS | 1 |
| Chao, CJ | 1 |
| Lin, GD | 1 |
| Yao, TJ | 1 |
| Huang, JD | 1 |
| Chen, PJ | 1 |
| Tsai, HJ | 1 |
| Jan, CM | 1 |
| Wang, YH | 1 |
| Chiou, HE | 1 |
| Wang, YY | 1 |
| Liu, HW | 1 |
| Bölke, E | 1 |
| Gripp, S | 1 |
| Peiper, M | 1 |
| Budach, W | 1 |
| Schwarz, A | 1 |
| Orth, K | 1 |
| Reinecke, P | 1 |
| van de Nes, JA | 1 |
| Han, SH | 1 |
| Park, SH | 1 |
| Kim, JH | 2 |
| Lee, JJ | 1 |
| Kwon, SY | 1 |
| Kwon, OS | 1 |
| Kim, SS | 1 |
| Kim, KK | 1 |
| Park, YH | 1 |
| Lee, JN | 1 |
| Nam, E | 1 |
| Bang, SM | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Lee, JH | 1 |
| Chuah, B | 1 |
| Lim, R | 1 |
| Boyer, M | 1 |
| Ong, AB | 1 |
| Wong, SW | 1 |
| Kong, HL | 1 |
| Millward, M | 1 |
| Clarke, S | 1 |
| Goh, BC | 1 |
| Chiou, CC | 1 |
| Shih, IH | 1 |
| Chang, YC | 1 |
| Lee, JC | 1 |
| Kuo, SC | 1 |
| Hong, HS | 1 |
| Yang, CH | 1 |
| Hao, MZ | 1 |
| Lin, HL | 1 |
| Chen, Q | 1 |
| Wu, H | 1 |
| Yu, WC | 1 |
| Chen, TG | 1 |
| Demeria, D | 1 |
| Birchall, I | 1 |
| Bain, VG | 1 |
| Wong, H | 1 |
| Ng, KK | 1 |
| Chok, SH | 1 |
| Cheung, TT | 1 |
| Lam, V | 1 |
| Epstein, RJ | 1 |
| Fan, ST | 1 |
| Saccomanni, G | 1 |
| Turini, V | 1 |
| Manera, C | 1 |
| Placanica, G | 1 |
| Salè, EO | 1 |
| Jemos, C | 1 |
| Giorgi, M | 1 |
| Macchia, M | 1 |
| Wördemann, M | 1 |
| Fandrey, J | 1 |
| Jelkmann, W | 1 |
| Konno, H | 1 |
| Tanaka, T | 1 |
| Baba, M | 1 |
| Kanai, T | 1 |
| Nakamura, S | 1 |
| Ellis, LM | 1 |
| Peterson, JA | 1 |
| Waugh, KA | 1 |
| Politi, PM | 1 |
| Escudier, B | 1 |
| Lassau, N | 1 |
| Leborgne, S | 1 |
| Angevin, E | 1 |
| Laplanche, A | 1 |
| Walters, MA | 2 |
| Katsuta, H | 1 |
| Takaoka, T | 1 |
| Gershbein, LL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lenalidomide to Reverse Drug Resistance After Lenvatinib Combined With PD-1 Inhibitors in the First-line Treatment of Advanced HCC ：a Prospective, Exploratory, Single-arm, Open-label, Multi-center Clinical Study[NCT05831969] | Phase 2 | 23 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial[NCT01545804] | Phase 2 | 55 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial[NCT00717756] | Phase 2 | 41 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Phase 1/2 Study of Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors[NCT01166035] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2010-03-31 | Recruiting | ||
| [NCT00006198] | Phase 2 | 0 participants | Interventional | Active, not recruiting | |||
| A Pilot Clinical and Mechanistic Study of Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma[NCT00155272] | Phase 1/Phase 2 | 19 participants | Interventional | 2005-03-31 | Recruiting | ||
| A Phase I Open-label Dose-escalation Study With Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma[NCT01348503] | Phase 1 | 5 participants (Actual) | Interventional | 2011-05-31 | Terminated (stopped due to Treatment was ineffective) | ||
| Thalidomide for Unresectable Hepatocellular Cancer With Optional Interferon Alpha-2a Upon Disease Progression[NCT00006006] | Phase 2 | 38 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"radiographic response defined as partial response defined by RECIST:At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD~It is noted that while on average the time frame for scans was 4 months, there were two patients who at 32 and 36 months had not progressed." (NCT00717756)
Timeframe: on average about every 2 months until progression, on average about 4 months.
| Intervention | participants (Number) |
|---|---|
| Lenalidomide | 6 |
7 reviews available for thalidomide and Cancer of Liver
| Article | Year |
|---|---|
Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combin | 2017 |
Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modalit | 2018 |
Hepatic epithelioid hemangioendothelioma metastasized to the peritoneum, omentum and mesentery: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Diagnosis, Differential; | 2015 |
Evolution of systemic therapy of advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; | 2008 |
Hepatocellular carcinoma with intra-atrial tumor thrombi. A report of three cases responsive to thalidomide treatment and literature review.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Heart Atria; Humans; Liver Neoplasms | 2004 |
Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Endothelial Growth Factors; Female; Gas | 1999 |
[Thalidomide. Clinical trials in cancer].
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Multiple Myeloma; | 2000 |
19 trials available for thalidomide and Cancer of Liver
| Article | Year |
|---|---|
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Chronic thalidomide and chemoembolization for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Live | 2014 |
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Combined Modality Therapy; Contrast Media; | 2015 |
Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellu | 2016 |
Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Le | 2016 |
Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Capillaries; Carcinoma, Hepatocellular; Dos | 2008 |
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal | 2008 |
Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Chemokine | 2012 |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combin | 2012 |
Salvage therapy for hepatocellular carcinoma with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Female; Humans; | 2004 |
Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Disease-Free Sur | 2005 |
Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Disease Progression; Female; Humans | 2005 |
Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2005 |
A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Double-Blin | 2005 |
Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality | 2006 |
Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Angiogenesis Inhibitors; Area Under Curve; | 2006 |
Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; | 2007 |
[Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial].
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Chemoemboliza | 2007 |
57 other studies available for thalidomide and Cancer of Liver
| Article | Year |
|---|---|
Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Lenalidomide; Liver | 2016 |
In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Dose-Response R | 2021 |
Isotretinoin and Thalidomide Down-Regulate
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down | 2021 |
Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma.
Topics: AIDS-Related Opportunistic Infections; Angiogenesis Inhibitors; Antiretroviral Therapy, Highly Activ | 2013 |
Lipid droplet binding thalidomide analogs activate endoplasmic reticulum stress and suppress hepatocellular carcinoma in a chemically induced transgenic mouse model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Pro | 2013 |
Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.
Topics: Adenomatous Polyposis Coli; Adult; Angiogenesis Inhibitors; Antibody-Dependent Cell Cytotoxicity; An | 2014 |
Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Cisplatin; Combine | 2014 |
Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma.
Topics: Aged; Angiogenesis Inhibitors; Antigens, CD34; Biomarkers, Tumor; Biopsy; Hemangioendothelioma, Epit | 2014 |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Disease Model | 2014 |
Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapy.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Magnetic Resona | 2015 |
Lenalidomide induces apoptosis and inhibits angiogenesis via caspase‑3 and VEGF in hepatocellular carcinoma cells.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Pro | 2016 |
Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Ce | 2008 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2009 |
The antiangiogenic effect of thalidomide on occult liver metastases: an in vivo study in mice.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Colonic Neoplasms; Female; Image Processing, Compu | 2009 |
[Inhibitory effect of thalidomide on growth of human hepatoma cell line SMMC-7721 cells].
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Pro | 2009 |
Antiangiogenic therapy combined with TACE - more beneficial therapeutic effect in HCC.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Therapy, Co | 2010 |
Contrast-enhanced ultrasonic parametric perfusion imaging in the evaluation of antiangiogenic tumor treatment.
Topics: Angiogenesis Inhibitors; Animals; Area Under Curve; Carcinoma, Hepatocellular; Contrast Media; Disea | 2012 |
Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2012 |
Angiosarcoma of the liver with metastasis to the cervical spine cured with the treatment of thalidomide and radiotherapy.
Topics: Angiogenesis Inhibitors; Biopsy; Cervical Vertebrae; Chemoradiotherapy; Hemangiosarcoma; Humans; Liv | 2012 |
Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Ka | 2012 |
Effect of an angiogenesis inhibitor on hepatic tumor perfusion and the implications for adjuvant cytotoxic therapy.
Topics: Angiogenesis Inhibitors; Animals; Contrast Media; Disease Models, Animal; Immunohistochemistry; Iohe | 2012 |
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophos | 2012 |
Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Cyprohepta | 2012 |
Signet ring-like light chain myeloma with systemic spread.
Topics: Anemia; Antineoplastic Agents; Bone Marrow Examination; Combined Modality Therapy; Diagnostic Errors | 2003 |
THALIDOMIDE AND NEOPLASIA.
Topics: Carcinogens; Carcinoma, Hepatocellular; Liver Neoplasms; Lymphoma; Mice; Neoplasms; Neoplasms, Exper | 1963 |
Low-dose thalidomide treatment for advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Carcinoma, Hepatocel | 2003 |
[Effect of thalidomide on tumor growth in mouse hepatoma H22 model].
Topics: Angiogenesis Inhibitors; Animals; Body Weight; Carcinoma, Hepatocellular; Disease Models, Animal; Fl | 2003 |
Angiosarcoma of the small intestine: a possible role for thalidomide?
Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Angiogenesis Inhibitors; Hemangiosarcoma; Humans; | 2003 |
Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liv | 2004 |
Thalidomide for advanced hepatocellular carcinoma: is this a real alternative?
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; | 2005 |
Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Division; DNA Prime | 2005 |
Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; H | 2004 |
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Human | 2005 |
Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Carcinoma, Hepatocellular; Fibroblast Grow | 2005 |
Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Angiogenesis Inducing Agents; Angiogenesis Inhib | 2005 |
Effect of thalidomide on colorectal cancer liver metastases in CBA mice.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Fibroblast Growth Fact | 2005 |
alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Dis | 2005 |
Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cytokines; Disease Progression; Drug Ther | 2005 |
Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Image Proc | 2006 |
Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Thal | 2006 |
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration | 2006 |
Low dose of thalidomide can be effective in advanced hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Severity | 2006 |
Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Dose-Response Re | 2006 |
Multifocal epithelioid hemangioendothelioma: case report of a clinical chamaeleon.
Topics: Angiogenesis Inhibitors; Diagnosis, Differential; Fatal Outcome; Hemangioendothelioma, Epithelioid; | 2006 |
Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study.
Topics: Adult; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Immunosuppressi | 2006 |
Thalidomide-induced severe facial erythema in a patient with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Erythema; Humans; Immunosuppressive Agents; Liver Neoplasms; Male; | 2007 |
Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male | 2007 |
Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Ankle; Carcinoma, Hepatocellular; Edema; Fe | 2007 |
High performance liquid chromatographic determination of thalidomide in patients affected by hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Humans; Li | 2008 |
Tumor necrosis factor-alpha production by human hepatoma cell lines is resistant to drugs that are inhibitory to macrophages.
Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Cyclosporine; Drug Resistance, Neoplasm; Humans; | 1998 |
Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide.
Topics: Administration, Oral; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; | 2000 |
Thalidomide and venous thrombosis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Liver Neoplasms; Thalidomide; Venous Thrombo | 2002 |
Tumour-incidence in progeny of thalidomide-treated mice.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Carcinoma, Hepatocellular; Female; Hodgkin D | 1967 |
Sensitivity of newborn mice to carcinogenic agents.
Topics: Adenocarcinoma; Adenoma; Animals; Animals, Newborn; Benz(a)Anthracenes; Carcinogens; Carcinoma, Hepa | 1968 |
Carcinogenesis in tissue culture. 3. Effects of the second treatments on DAB-induced proliferating liver cells of normal rats in culture.
Topics: Animals; Carcinogens; Culture Techniques; Growth Hormone; Liver Neoplasms; Neoplasm Transplantation; | 1965 |
Effect of various agents on liver regeneration and Walker tumor growth in partially hepatectomized rats.
Topics: Animals; Antineoplastic Agents; Benz(a)Anthracenes; Benzofurans; Carcinoma 256, Walker; Cortisone; D | 1966 |